Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 71:209–249

PubMed  Google Scholar 

Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Glüer CC, de Villiers T, Baber R, Roodman GD, Cooper C, Langdahl B, Palacios S, Kanis J, Al-Daghri N, Nogues X, Eriksen EF, Kurth A, Rizzoli R, Coleman RE (2017) Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 7:1–12

PubMed  PubMed Central  Article  Google Scholar 

(EBCTCG) EBCTCG (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (London, England) 386:1341–1352

Article  CAS  Google Scholar 

Mazziotti G, Canalis E, Giustina A (2010) Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 123:877–884

CAS  PubMed  Article  Google Scholar 

Hadji P (2009) Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 69:73–82

PubMed  Article  Google Scholar 

Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet (London, England) 365:60–62

CAS  Article  Google Scholar 

Lems WF, Paccou J, Zhang J, Fuggle NR, Chandran M, Harvey NC, Cooper C, Javaid K, Ferrari S, Akesson KE (2021) Vertebral fracture: epidemiology, impact and use of DXA vertebral fracture assessment in fracture liaison services. Osteoporos Int 32:399–411

CAS  PubMed  PubMed Central  Article  Google Scholar 

Pedersini R, Monteverdi S, Mazziotti G, Amoroso V, Roca E, Maffezzoni F, Vassalli L, Rodella F, Formenti AM, Frara S, Maroldi R, Berruti A, Simoncini E, Giustina A (2017) Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: a cross-sectional study. Bone 97:147–152

CAS  PubMed  Article  Google Scholar 

Adachi JD, Adami S, Gehlbach S, Anderson FA Jr, Boonen S, Chapurlat RD, Compston JE, Cooper C, Delmas P, Díez-Pérez A, Greenspan SL, Hooven FH, LaCroix AZ, Lindsay R, Netelenbos JC, Wu O, Pfeilschifter J, Roux C, Saag KG, Sambrook PN, Silverman S, Siris ES, Nika G, Watts NB (2010) Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc 85:806–813

PubMed  PubMed Central  Article  Google Scholar 

Jalava T, Sarna S, Pylkkänen L, Mawer B, Kanis JA, Selby P, Davies M, Adams J, Francis RM, Robinson J, McCloskey E (2003) Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 18:1254–1260

PubMed  Article  Google Scholar 

Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, Smith S, Edwards BJ, Frank E, Lyman GH, Smith MR, Mhaskar R, Henderson T, Neuner J (2019) Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol 37:2916–2946

PubMed  Article  Google Scholar 

Miyashita H, Satoi S, Kuno T, Cruz C, Malamud S, Kim SM (2020) Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis. Breast Cancer Res Treat 181:279–289

CAS  PubMed  Article  Google Scholar 

Bassatne A, Bou Khalil A, Chakhtoura M, Arabi A, Van Poznak C, El-Hajj Fuleihan G (2021) Effect of antiresorptive therapy on aromatase inhibitor induced bone loss in postmenopausal women with early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Metabolism 128:154962

PubMed  Article  CAS  Google Scholar 

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (London, England) 370:1453–1457

Article  Google Scholar 

Rossini M, Adami S, Bertoldo F, Diacinti D, Gatti D, Giannini S, Giusti A, Malavolta N, Minisola S, Osella G, Pedrazzoni M, Sinigaglia L, Viapiana O, Isaia GC (2016) Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo 68:1–39

CAS  PubMed  Article  Google Scholar 

Dalla Volta A, Mazziotti G, Maffezzoni F, Grisanti S, Palumbo C, Pedersini R, Maroldi R, Berruti A (2020) Bone mineral density and FRAX score may not predict fracture risk in patients with cancer undergoing hormone deprivation therapies. J Clin Oncol 38:3363–3366

PubMed  Article  Google Scholar 

Mazziotti G, Vena W, Pedersini R, Piccini S, Morenghi E, Cosentini D, Zucali P, Torrisi R, Sporeni S, Simoncini EL, Maroldi R, Balzarini L, Lania AG, Berruti A (2022) Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: reliability of who fracture risk assessment tool (frax) and bone mineral density in real-life clinical practice. J Bone Oncol 33:100421

PubMed  PubMed Central  Article  Google Scholar 

Clark EM, Carter L, Gould VC, Morrison L, Tobias JH (2014) Vertebral fracture assessment (VFA) by lateral DXA scanning may be cost-effective when used as part of fracture liaison services or primary care screening. Osteoporos Int 25:953–964

CAS  PubMed  Article  Google Scholar 

Griffith JF, Genant HK (2012) New advances in imaging osteoporosis and its complications. Endocrine 42:39–51

CAS  PubMed  Article  Google Scholar 

Engelke K, Stampa B, Steiger P, Fuerst T, Genant HK (2019) Automated quantitative morphometry of vertebral heights on spinal radiographs: comparison of a clinical workflow tool with standard 6-point morphometry. Arch Osteoporos 14:18

PubMed  Article  Google Scholar 

Crans GG, Genant HK, Krege JH (2005) Prognostic utility of a semiquantitative spinal deformity index. Bone 37:175–179

PubMed  Article  Google Scholar 

Schousboe JT, Shepherd JA, Bilezikian JP, Baim S (2013) Executive summary of the 2013 international society for clinical densitometry position development conference on bone densitometry. J Clin Densitom 16:455–466

PubMed  Article  Google Scholar 

Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397

CAS  PubMed  PubMed Central  Article  Google Scholar 

Lindsay R, Pack S, Li Z (2005) Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis. Osteoporos Int 16:306–312

PubMed  Article  Google Scholar 

Mirza F, Canalis E (2015) Management of endocrine disease: secondary osteoporosis: pathophysiology and management. Eur J Endocrinol 173:R131-151

CAS  PubMed  PubMed Central  Article  Google Scholar 

Pedersini R, Amoroso V, Maffezzoni F, Gallo F, Turla A, Monteverdi S, Ardine M, Ravanelli M, Vassalli L, Rodella F, Formenti AM, Dalla Volta A, Simoncini EL, Giustina A, Maroldi R, Berruti A (2019) Association of fat body mass with vertebral fractures in postmenopausal women with early breast cancer undergoing adjuvant aromatase inhibitor therapy. JAMA Netw Open 2:e1911080

PubMed  PubMed Central  Article  Google Scholar 

Mazziotti G, Lania AG, Canalis E (2022) Skeletal disorders associated with the growth hormone-insulin-like growth factor 1 axis. Nat Rev Endocrinol. https://doi.org/10.1038/s41574-022-00649-8

Article  PubMed  Google Scholar 

Lu H, Lei X, Zhao H, Elting L, Siricilla M, Ursani MA, Giordano SH, Suarez-Almazor M (2021) Bone mineral density at the time of initiating aromatase inhibitor therapy is associated with decreased fractures in women with breast cancer. J Bone Miner Res 36:861–871

CAS  PubMed  Article  Google Scholar 

Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD (2007) Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prev Bisphosphonates Bone 41:346–352

CAS  Article  Google Scholar 

Pineda-Moncusí M, Garcia-Giralt N, Diez-Perez A, Servitja S, Tusquets I, Prieto-Alhambra D, Nogués X (2020) Increased fracture risk in women treated with aromatase inhibitors versus tamoxifen: beneficial effect of bisphosphonates. J Bone Miner Res 35:291–297

PubMed  Article  CAS  Google Scholar 

Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet (London, England) 386:433–443

CAS  Article  Google Scholar 

Sun S, Wang F, Dou H, Zhang L, Li J (2016) Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole. Onco Targets Ther 9:6029–6036

CAS  PubMed  PubMed Central  Article  Google Scholar 

Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, von Minckwitz G, Miller J, Schenk N, Coleman R (2010) Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 21:2188–2194

CAS  PubMed  Article  Google Scholar 

Monda V, Lupoli GA, Messina G, Peluso R, Panico A, Villano I, Salerno M, Sessa F, Marciello F, Moscatelli F, Valenzano A, Molino L, Lupoli R, Fonderico F, Tortora A, Pisano A, Ruberto M, Gabriella M, Cavaliere G, Trinchese G, Mollica MP, Cipolloni L, Cibelli G, Monda M, Lupoli G, Messina A (2017) Improvement of bone physiology and life quality due to association of risedronate and anastrozole. Front Pharmacol 8:632

PubMed  PubMed Central  Article  CAS  Google Scholar 

Buch-Larsen K, Jørgensen NR, Jensen LT, Andersson M, Schwarz P (2021) Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study. Scand J Clin Lab Invest 81:425–431

CAS  PubMed  Article  Google Scholar 

van de Glind EM, Willems HC, Eslami S, Abu-Hanna A, Lems WF,